Chimeric Therapeutics Limited (CHM.AX)
- Previous Close
0.0290 - Open
0.0300 - Bid 0.0290 x 24502200
- Ask 0.0300 x 16334300
- Day's Range
0.0290 - 0.0300 - 52 Week Range
0.0230 - 0.0730 - Volume
388,985 - Avg. Volume
2,523,018 - Market Cap (intraday)
25.554M - Beta (5Y Monthly) 1.72
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0300 - Earnings Date Feb 29, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Chimeric Therapeutics Limited, a clinical stage cell therapy company, develops and commercializes a range of cell therapies in oncology in Australia. The company develops CHM 0201 (core NK platform) that is in phase I clinical trial for treating solid tumors and hematological malignancies; and CHM 1101 (CLTX CAR T), which is in phase I clinical trial for treating patients with MMP2+ recurrent or progressive glioblastoma. It is also developing CHM 0301 for blood cancers; CHM 1301 (CLTX CAR NK) and CHM 2301 (CDH17 CAR NK) for solid tumors; CHM 1101 (CLTX CAR T) for melanoma, colorectal, and prostate; and CHM 2101 (CDH17 CAR T) for neuroendocrine, colorectal, pancreatic, and gastric. The company was incorporated in 2020 and is based in Carlton, Australia.
www.chimerictherapeutics.comRecent News: CHM.AX
Performance Overview: CHM.AX
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: CHM.AX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: CHM.AX
Valuation Measures
Market Cap
25.55M
Enterprise Value
22.03M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
1.84
Enterprise Value/Revenue
8.33k
Enterprise Value/EBITDA
-2.14
Financial Highlights
Profitability and Income Statement
Profit Margin
-94.06%
Return on Assets (ttm)
-29.41%
Return on Equity (ttm)
-78.65%
Revenue (ttm)
12.47M
Net Income Avi to Common (ttm)
-11.73M
Diluted EPS (ttm)
-0.0300
Balance Sheet and Cash Flow
Total Cash (mrq)
3.53M
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-6.09M
Company Insights: CHM.AX
CHM.AX does not have Company Insights